SUNDAY |
2:00 pm - 9:00 pm | Arrival and Check-in (Office Closed 6:00 pm - 7:00 pm) |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 7:50 pm | Welcome: Donald Tweedie (Boehringer Ingelheim) |
7:50 pm - 9:30 pm | Opening Session - The Past is Prologue |
7:50 pm - 9:00 pm | Larry Lesko (FDA)
"Making Shakespeare Proud: Let's Get to a Regulatory Perspective on Drug Metabolism" |
9:00 pm - 9:30 pm | Discussion |
MONDAY |
7:30 am - 8:30 am | Breakfast |
8:45 am | Group Photo |
9:00 am - 12:30 pm | Drug-Drug Interactions: Are We Providing Solutions? |
| Discussion Leader: Lisa Shipley (Merck & Co) |
9:00 am - 9:30 am | Kellie S. Reynolds (Division of Clinical Pharmacology, FDA)
"Drug Interaction Information in Product Labels - After the evolution, is it time for a revolution?" |
9:30 am - 9:45 am | Discussion |
9:45 am - 10:15 am | Dan Cui (Merck & Co.)
"Impact of DMPK in Drug Discovery and Drug Development: Case Examples of Prospective and Retrospective Assessment of Drug-Drug Interactions" |
10:15 am - 10:30 am | Discussion |
10:30 am | Coffee Break |
11:00 am - 11:30 am | Lan Ni (Eli Lilly and Company)
"Clinical Drug-Drug Interaction Study: How Many Is Enough?" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Lewis J. Klunk (Biogen Idec)
"Biotherapeutics and Small Drug Molecule Interaction Studies: Are they Scientifically Rational?" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Translating Nonclinical and Clinical Knowledge: Using the Quantitative Model Based Development Approach |
| Discussion Leader: Sandy Allerheiligen (Eli Lilly & Co) |
7:30 pm - 8:00 pm | Douglas Lauffenburger (Massachusetts Institute of Technology)
"Quantitative Systems Analysis of Cell Responses to Drugs and Cytokines" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:40 pm | Joe Balthazar (University of Buffalo)
"Quantitative Approaches to Discovery/Development of Large Molecules: Learning from Antibodies" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Richard Lalonde (Pfizer)
"Quantitative Use of Prior Data in Clinical Drug Development" |
9:20 pm - 9:30 pm | Discussion |
TUESDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Drug Transporters: Potential for Drug-Drug Interactions and Correlation with Organ Toxicity |
| Discussion Leader: Raymond Evers (Merck & Co.) |
9:00 am - 9:30 am | Mikko Niemi (University of Helsinki)
"Role of Transporter Pharmacogenetics in the Disposition of Statins" |
9:30 am - 9:45 am | Discussion |
9:45 am - 10:15 am | Nathan Cherrington (University of Arizona)
"Identifying Patients with Altered ADME at Risk of Adverse Drug Reactions" |
10:15 am - 10:30 am | Discussion |
10:30 am | Coffee Break |
11:00 am - 11:30 am | Maarten Huisman (Johnson and Johnson)
"Recent Experiences with Transporter Issues at J&J" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Christopher MacLauchlin (GlaxoSmithKline)
"Clinical Efficacy and Toxicity of Lapatinib: Deciphering the Role of Transporters" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Transporter/Phase II Drug Metabolizing Enzyme Interplay |
| Discussion Leader: K. Sandy Pang (University of Toronto) |
7:30 pm - 8:00 pm | Dietrich Keppler (German Cancer Research Center)
"Transport of Phase-II Conjugation Products by MRP2, MRP3, and MRP4" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:40 pm | Kim L.R. Brouwer (University of North Carolina)
"Role of Canalicular and Basolateral Transport Proteins in Determining Hepatocyte Exposure and Excretory Routes of Phase II Conjugates: A Kinetic Analysis" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Huadong Sun (University of Toronto)
"Transporter/Phase II Drug Metabolizing Enzyme Interplay: Impact of Futile Cycling" |
9:20 pm - 9:30 pm | Discussion |
WEDNESDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Pathophysiological Regulation of Drug Disposition Protein Turnover |
| Discussion Leader: Bernard Murray (Gilead Sciences) |
9:00 am - 9:30 am | Randy Hampton (University of California, San Diego)
"Protein Quality Control as a Strategy of Cellular Regulation: Lessons from ERAD of HMG-CoA Reductase" |
9:30 am - 9:45 am | Discussion |
9:45 am - 10:15 am | M. Almira Correia (University of California, San Francisco)
"Molecular Partnerships, Functional Interactions and Funereal Modifications Along the Cytochrome P450 Degradation Trail" |
10:15 am - 10:30 am | Discussion |
10:30 am | Coffee Break |
11:00 am - 11:30 am | Magang Shou (Amgen)
"Modeling of Hepatocyte CYP Induction for Dose-Response Relationship and Prediction of Drug Interactions" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Yanan Tian (Texas A&M)
"Interaction Between Pregnane X Receptor and NF-kB: Mechanism of Suppression of Drug/Xenobiotic Metabolism by Inflammatory Responses" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:00 pm - 7:30 pm | Business Meeting |
| (Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair) |
7:30 pm - 9:30 pm | Graduate Student and Post-Doc Presentations |
| Discussion Leader: Henry Strobel (University of Texas at Houston) |
7:30 pm - 7:45 pm | Howard Horng (University of California, San Francisco)
"The Characterization of the Acyl-Linked Metabolite, Mefenamyl-Adenylate" |
7:45 pm - 7:50 pm | Discussion |
7:50 pm - 8:05 pm | Jin Zhou (University of Minnesota)
"Glucuronidation of Dihydrotestosterone and Trans-androsterone by Recombinant UGT1A4: Evidence for Multiple UGT1A4 Aglycone Binding Sites" |
8:05 pm - 8:10 pm | Discussion |
8:10 pm - 8:25 pm | Poulomi Acharya (University of California, San Francisco)
"CYP3A ER-associated degradation (ERAD) in human and rat hepatocytes: Characterization of the functional role of p97 AAA-ATPase" |
8:25 pm - 8:30 pm | Discussion |
8:30 pm - 8:45 pm | Zhi Xia Yan (University of North Carolina)
"Comparison of the Hepatobiliary Disposition of Two Antiparasitic Agents in Sandwich-Cultured Hepatocytes and Isolated Perfused Livers from Rats" |
8:45 pm - 8:50 pm | Discussion |
8:50 pm - 9:05 pm | Matthew Danielson (Purdue University)
"Novel Computational Methods to Model CYP2C9" |
9:05 pm - 9:10 pm | Discussion |
9:10 pm - 9:25 pm | Maribel Reyes (University of California, San Francisco)
"Effects of uremic serum on hepatic uptake, metabolism, and disposition of three BDDCS drugs using in vitro and ex situ systems" |
9:25 pm - 9:30 pm | Discussion |
THURSDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Models and Biomarkers of Drug Induced Liver Injury |
| Discussion Leader: Robert Roth (Michigan State University) |
9:00 am - 9:30 am | Ivan Rusyn (University of North Carolina)
"Mouse Model of the Human Population: Application to Studies of Liver Toxicity" |
9:30 am - 9:45 am | Discussion |
9:45 am - 10:15 am | Patricia Ganey (Michigan State University)
"Multiple Modes of Action in an Inflammatory Stress-Drug Interaction Model of Idiosyncratic Liver Injury" |
10:15 am - 10:30 am | Discussion |
10:30 am | Coffee Break |
11:00 am - 11:30 am | Russell Thomas (The Hamner Institute)
"Developing Circulating mRNA Biomarkers for Hepatotoxicity" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Robert Roth (Michigan State University)
"A Murine Model of Idiosyncratic Halothane Hepatotoxicity" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Reception |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Preclinical Identification of Reactive Intermediates: Defining the Clinical Value |
| Discussion Leader: Donald Tweedie (Boehringer Ingelheim) |
7:30 pm - 8:00 pm | Kevin Park (University of Liverpool)
"Physiological, Pharmacological and Toxicological Consequences of Drug Bioactivation" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:25 pm | Deborah Nicoll-Griffith (Merck & Co.)
"Merck Covalent Binding Strategy - 5 Years Down the Road" |
8:25 pm - 8:30 pm | Discussion |
8:30 pm - 8:45 pm | Yan Li (AstraZeneca)
"Integrated Risk Assessment for Reactive Metabolite - AstraZeneca's Approach" |
8:45 pm - 8:50 pm | Discussion |
8:50 pm - 9:05 pm | Scott Obach (Pfizer)
"Safe Compounds Sometimes Covalently Bind In Vitro and Toxic Ones Sometimes Do Not. Can We Successfully Use Reactive Metabolite Data in Drug Research?" |
9:05 pm - 9:10 pm | Discussion |
9:10 pm - 9:30 pm | Round Table Discussion |
FRIDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am | Depart |